Literature DB >> 24059296

Current acetylcholinesterase-inhibitors: a neuroinformatics perspective.

Sibhghatulla Shaikh, Anupriya Verma, Saimeen Siddiqui, Syed S Ahmad, Syed M D Rizvi, Shazi Shakil, Deboshree Biswas, Divya Singh, Mohmmad H Siddiqui, Shahnawaz Shakil, Shams Tabrez, Mohammad A Kamal1.   

Abstract

This review presents a concise update on the inhibitors of the neuroenzyme, acetylcholinesterase (AChE; EC 3.1.1.7). AChE is a serine protease, which hydrolyses the neurotransmitter, acetylcholine into acetate and choline thereby terminating neurotransmission. Molecular interactions (mode of binding to the target enzyme), clinical applications and limitations have been summarized for each of the inhibitors discussed. Traditional inhibitors (e.g. physostigmine, tacrine, donepezil, rivastigmine etc.) as well as novel inhibitors like various physostigmine-derivatives have been covered. This is followed by a short glimpse on inhibitors derived from nature (e.g. Huperzine A and B, Galangin). Also, a discussion on 'hybrid of pre-existing drugs' has been incorporated. Furthermore, current status of therapeutic applications of AChEinhibitors has also been summarized.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24059296     DOI: 10.2174/18715273113126660166

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  9 in total

Review 1.  Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus.

Authors:  Gohar Mushtaq; Nigel H Greig; Jalaluddin A Khan; Mohammad A Kamal
Journal:  CNS Neurol Disord Drug Targets       Date:  2014       Impact factor: 4.388

Review 2.  Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models.

Authors:  Lauren C Smith; Olivier George
Journal:  Neuropharmacology       Date:  2020-08-03       Impact factor: 5.250

Review 3.  Peptides Derived from Growth Factors to Treat Alzheimer's Disease.

Authors:  Suzanne Gascon; Jessica Jann; Chloé Langlois-Blais; Mélanie Plourde; Christine Lavoie; Nathalie Faucheux
Journal:  Int J Mol Sci       Date:  2021-06-04       Impact factor: 5.923

4.  Synthesis and molecular docking studies of some 4-phthalimidobenzenesulfonamide derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors.

Authors:  Zeynep Soyer; Sirin Uysal; Sulunay Parlar; Ayse Hande Tarikogullari Dogan; Vildan Alptuzun
Journal:  J Enzyme Inhib Med Chem       Date:  2016-10-21       Impact factor: 5.051

5.  Folecitin Isolated from Hypericum oblongifolium Exerts Neuroprotection against Lipopolysaccharide-Induced Neuronal Synapse and Memory Dysfunction via p-AKT/Nrf-2/HO-1 Signalling Pathway.

Authors:  Umar Farooq; Muhammad Umar Khayam Sahibzada; Taous Khan; Rahim Ullah; Muhammad Shahid; Ameer Khusro; Veronique Seidel; Magda H Abdellattif; Talha Bin Emran
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-28       Impact factor: 2.629

Review 6.  Study of Nutraceuticals and Phytochemicals for the Management of Alzheimer's Disease: A Review.

Authors:  Syed Sayeed Ahmad; Mohammad Khalid; Mohammad A Kamal; Kaiser Younis
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708

7.  Integrated comparative metabolomics and network pharmacology approach to uncover the key active ingredients of Polygonati rhizoma and their therapeutic potential for the treatment of Alzheimer's disease.

Authors:  Fu Wang; Hongping Chen; Yuan Hu; Lin Chen; Youping Liu
Journal:  Front Pharmacol       Date:  2022-08-04       Impact factor: 5.988

8.  Aberrant DNA Methylation of rDNA and PRIMA1 in Borderline Personality Disorder.

Authors:  Stefanie Teschler; Julia Gotthardt; Gerhard Dammann; Reinhard H Dammann
Journal:  Int J Mol Sci       Date:  2016-01-05       Impact factor: 5.923

Review 9.  Role of Plant Derived Alkaloids and Their Mechanism in Neurodegenerative Disorders.

Authors:  Ghulam Hussain; Azhar Rasul; Haseeb Anwar; Nimra Aziz; Aroona Razzaq; Wei Wei; Muhammad Ali; Jiang Li; Xiaomeng Li
Journal:  Int J Biol Sci       Date:  2018-03-09       Impact factor: 6.580

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.